Sign In
Buy RYTM
$99.25
-6.49 (-6.14%)
At Close: Jul 31, 2026
Rhythm Pharmaceuticals Q4 Beat Sets Stage For March 20th PDUFA Decision
07:30am, Monday, 16'th Mar 2026
Rhythm Pharmaceuticals delivered strong FY25 revenue growth, driven by global demand for IMCIVREE (setmelanotide), reaching $194.8 million, up 50% year-over-year. RYTM's upcoming March 20th FDA PDUFA
Cinctive Capital Management LP Sells 35,781 Shares of Rhythm Pharmaceuticals, Inc. $RYTM
04:31am, Monday, 16'th Mar 2026
Cinctive Capital Management LP decreased its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) by 50.4% in the undefined quarter, according to the company in its most recent 13F filing with the
Rhythm Pharmaceuticals Discloses 18.8% BMI Drop In Rare Obesity Patients
09:41am, Monday, 02'nd Mar 2026
Rhythm Pharma shares rise after Phase 3 data show strong BMI drop. FDA decision on obesity drug due by March 20.
-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity -- -
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2025 Earnings Call Transcript
03:08pm, Thursday, 26'th Feb 2026
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Beats Revenue Estimates
10:56am, Thursday, 26'th Feb 2026
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to a loss of $0.72 per share a year ago.
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
07:00am, Thursday, 26'th Feb 2026
-- Fourth quarter 2025 net product revenue from global sales of IMCIVREE ® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic
Hillsdale Investment Management Inc. Takes $4.30 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM
06:10am, Monday, 23'rd Feb 2026
Hillsdale Investment Management Inc. purchased a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) during the undefined quarter, according to the company in its most recent 13F filing with t
Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market
12:42pm, Thursday, 19'th Feb 2026
RBC Capital Markets initiated coverage on Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM), citing it as a commercial-stage biotech pioneering the rare genetic obesity market.
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Should You Buy?
11:00am, Thursday, 19'th Feb 2026
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pre-Market Stock Futures: Futures are trading lower on Thursday, as Walmart's forward outlook was disappointing. Risk-on was back on Wednesday, as the stock market, which is off to its worst start of
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
08:00am, Tuesday, 17'th Feb 2026
BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar
Prediction: These 3 Stocks Will Crush the Market in 2026
12:45pm, Monday, 16'th Feb 2026
Alphabet is poised to convert much of its record Google Cloud backlog into recognized revenue this year. BeOne Medicines could soon win approval for a powerhouse blood cancer therapy.
Rhythm Pharmaceuticals Eyes March 20 HO PDUFA, Highlights IMCIVREE Growth at Guggenheim Conf.
02:05am, Monday, 16'th Feb 2026
Rhythm Pharmaceuticals (NASDAQ: RYTM) Chief Financial Officer Hunter Smith outlined the company's near-term regulatory catalyst, commercial preparation, and pipeline updates during a discussion at Gug
BGM Group (NASDAQ:BGM) vs. Rhythm Pharmaceuticals (NASDAQ:RYTM) Financial Contrast
04:44am, Tuesday, 10'th Feb 2026
Rhythm Pharmaceuticals (NASDAQ: RYTM - Get Free Report) and BGM Group (NASDAQ: BGM - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies bas
